West Pharmaceutical Services Inc

West Pharmaceutical Services Inc(WST)の株式分析

$384.020

+0.998 (+0.26%)終値時点

Loading chart…
高値
386.260
始値
382.740
出来高加重平均価格
383.52
出来高
511.19K
時価総額
23.95B
安値
380.280
売買代金
196.05M
EV/EBITDA(TTM)
27.19

West Pharmaceutical Services Inc. is a global manufacturer in the design and production of technologically advanced, integrated containment and delivery systems for injectable drugs and healthcare products. Its segments include Proprietary Products and West Vantage. Its Proprietary Products segment offers proprietary packaging, containment solutions and drug delivery systems, along with analytical lab services and other integrated services and solutions, primarily for biologic, generic and pharmaceutical drug customers. Its West Vantage segment serves as a fully integrated business, focused on the design, manufacture, and automated assembly of complex devices, as well as combination product assembly and packaging, primarily for pharmaceutical, diagnostic, and medical device customers. It also maintains collaborations to share technologies and market products with affiliates in Japan and Mexico. Its customers include generic, pharmaceutical, diagnostic, and medical device companies.

www.westpharma.com

AI分析 of West Pharmaceutical Services Inc (WST)

買い

West Pharmaceutical Services Inc is a good buy right now, trading at $384.02 with a strong recent performance of +4.92% over the last 5 days and a year-to-date change of +38.94%. The company has shown robust growth, with Q2 2026 sales increasing to $872 million, a 13.8% rise, and an adjusted EPS of $2.37, exceeding expectations by $0.29. However, the RSI is at 75.786, indicating it may be overbought, which is a risk to consider.

アナリスト評価(7)

-9.20% 下落余地
買い
4 買い
2 中立
1 売り
現在: 384.02
安値
285.00
平均
348.70
高値
375.00

Barclays

2026-10-07

目標株価

$440

オーバーウェイト

Morgan Stanley

2026-09-22

目標株価

$400

オーバーウェイト

UBS

2026-09-09

目標株価

$415

買い

Citi

2026-08-03

目標株価

$412

買い

Evercore ISI

2026-07-27

目標株価

$425

アウトパフォーム

バリュエーション指標

West Pharmaceutical Services Inc(WST)の現在の予想PERは37.04で、5年平均は41.22です。

予想PER

適正
5年平均 P/E
41.22
現在のP/E
37.04
割高
48.02
割安
34.42

予想EV/EBITDA

適正
5年平均 EV/EBITDA
26.84
現在のEV/EBITDA
27.19
割高
31.75
割安
21.92

予想PSR

適正
5年平均 P/S
7.51
現在のP/S
7.51
割高
9.10
割安
5.93

Alphio AI による WST の価格シナリオ

シナリオ価格は本年の最終月次予想レンジです。確率はモデルの固定ウェイト(25 / 50 / 25)であり、保証ではありません。

強

強気

強気 · 25%WST

$201.68

シナリオ価格

基

基本

基本 · 50%WST

$194.98

シナリオ価格

弱

弱気

弱気 · 25%WST

$174.26

シナリオ価格

WST を保有するクジラ

G

Generation Investment Management LLP

+ を保有WST

+10.11%

3か月リターン

N

Nan Shan Life Insurance Co., Ltd.

+ を保有WST

+7.50%

3か月リターン

W

Walter Scott & Partners Limited

+ を保有WST

+6.20%

3か月リターン

C

Curi Capital, LLC

+ を保有WST

+5.77%

3か月リターン

L

LGT Capital Partners Ltd.

+ を保有WST

+4.08%

3か月リターン

R

Riverbridge Partners, LLC

+ を保有WST

+4.04%

3か月リターン

WST のよくある質問 — Alphio AI が回答

West Pharmaceutical Services Inc. is a global manufacturer in the design and production of technologically advanced, integrated containment and delivery systems for injectable drugs and healthcare products. Its segments include Proprietary Products and West Vantage. Its Proprietary Products segment offers proprietary packaging, containment solutions and drug delivery systems, along with analytical lab services and other integrated services and solutions, primarily for biologic, generic and pharmaceutical drug customers. Its West Vantage segment serves as a fully integrated business, focused on the design, manufacture, and automated assembly of complex devices, as well as combination product assembly and packaging, primarily for pharmaceutical, diagnostic, and medical device customers. It also maintains collaborations to share technologies and market products with affiliates in Japan and Mexico. Its customers include generic, pharmaceutical, diagnostic, and medical device companies. It operates in the Healthcare sector (SURGICAL & MEDICAL INSTRUMENTS & APPARATUS industry).

West Pharmaceutical Services Inc is a good buy right now, trading at $384.02 with a strong recent performance of +4.92% over the last 5 days and a year-to-date change of +38.94%. The company has shown robust growth, with Q2 2026 sales increasing to $872 million, a 13.8% rise, and an adjusted EPS of $2.37, exceeding expectations by $0.29. However, the RSI is at 75.786, indicating it may be overbought, which is a risk to consider.

7 analysts cover WST: 4 rate it Buy, 2 Hold and 1 Sell. The average price target is 348.70.

コミュニティ

もっと見る ↗

投稿はまだありません

登録またはログインして議論に参加

本ページは調査目的であり、投資助言ではありません。モデルは誤ることがあります。過去の実績は将来の成果を保証しません。

取引を始める